Close

Baird Maintains an 'Outperform' on Optimer Pharmaceuticals (OPTR); Staying Put Despite Q2 Disappointment

Go back to Baird Maintains an 'Outperform' on Optimer Pharmaceuticals (OPTR); Staying Put Despite Q2 Disappointment